Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (71579)	5/25/2001 10:46:06 AM
From: Jim Spitz	Read Replies (1) \| Respond to of 122087

TIMMMMMMBEEEERRRRRRRR! GENE Stay in the Black! jimS

To: Anthony@Pacific who wrote (71579)	5/25/2001 2:20:16 PM
From: mmmary	Respond to of 122087

GENE slides: news Genome Therapeutics (GENE: news, msgs, alerts) slid more than 8 percent in afternoon action. The stock soared almost 100 percent this week after Ladenburg Thalmann initiated coverage of the Waltham, Mass., genome research firm with a "strong buy" rating and an $84 price target. This morning, Friedman, Billings, Ramsey slashed its rating on Genome to "market perform" from accumulate" because the shares have already eclipsed the firm's $10 price target and "company fundamentals have not changed" since it began coverage last week. "Unlike, selected peers, Human Genome Sciences, Millenium Pharmaceuticals, and Myriad Genetics, GENE has no clinical pipeline and no lead drug candidate selected for clinical trials," the firm said, adding that "irrational retail trading of 1.7 times the float since May 23 has inflated share price."